IL33 and cancer: In a recent study of pancreatic cancer, IL-33 has been reported to activate ILC2s that further induce tertiary lymphoid structures (lymphoid aggregates that in chronically inflamed tissues, including cancer, infection and inflammation) (Amisaki et al., 2025).